EXPRESSION OF THE DCC GENE IN HUMAN HEMATOLOGICAL MALIGNANCIES

被引:11
作者
MIYAKE, K [1 ]
INOKUCHI, K [1 ]
NOMURA, T [1 ]
机构
[1] NIPPON MED COLL,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN
关键词
DCC GENE; TUMOR SUPPRESSOR GENE; LEUKEMIA; MYELODYSPLASTIC SYNDROMES; LEUKEMOGENESIS;
D O I
10.3109/10428199409114135
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inactivation of the deleted in colorectal carcinoma (DCC) tumor suppressor gene has been reported not only in colorectal carcinoma but also in other human malignancies. In order to evaluate the role of the DCC gene in leukemogenesis, we examined DCC expression using the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Expression of the DCC was reduced or absent in 10 of 39 (26%) patients with acute myelogenous leukemia (AML), three of 13 (29%) patients with acute lymphocytic leukemia (ALL), seven of 33 (21%) patients with chronic myelogenous leukemia (CML), three of 39 (8%) patients with myelodysplastic syndromes (MDS), and five of nine (56%) patients with overt leukemia progressed from MDS. These findings suggest that inactivation of the DCC gene contributes to some instances of leukemogenesis.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 55 条
  • [1] Weinberg R.A., Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis, Cancer Res., 49, pp. 3713-3721, (1989)
  • [2] Fearon E.R., Vogelstein B., A genetic model for colorectal tumorigenesis, Cell, 61, pp. 759-767, (1990)
  • [3] Stanbridge E.J., Identifying tumor suppressor genes in human colorectal cancer, Science, 247, pp. 12-13, (1990)
  • [4] Thomas G., Delattre O., Olschwang S., Laurent-Puig P., Inherited and acquired genetic alterations in human colorectal cancer, Cancer J., 3, pp. 304-309, (1990)
  • [5] Goyette M.C., Cho K., Fasching C.L., Levy D.B., Kinzler K.W., Paraskeva C., Vogelstein B., Stan-bridge E.J., Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer, Mol. Cell. Biol., 12, pp. 1387-1395, (1992)
  • [6] Slingerland J.M., Minden M.D., Benchimol S., Mutation of the p53 gene in human acute myelogenous leukemia, Blood, 77, pp. 1500-1507, (1991)
  • [7] Fenaux P., Jonveaux P., Quiquandon I., Lai J.L., Pignon M., Loucheux-Lefebvre M.H., Bauters F., Berger R., Kerckaert J.P., P53 gene mutations in acute myeloid leukemia with 17p monosomy, Blood, 78, pp. 1652-1657, (1991)
  • [8] Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K., Hirai H., Ishikawa F., Takaku F., Mutations of the p53 gene in lymphoid leukemia, Blood, 77, pp. 1153-1156, (1991)
  • [9] Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R., p53 mutation in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 88, pp. 5413-5417, (1991)
  • [10] Ahuja H., Bar-Eli M., Advani S.H., Benchimol S., Cline M.J., Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia, Proc. Nail. Acad. Sci. USA., 86, pp. 6783-6787, (1989)